长效抗胆碱能药物/长效β2受体激动剂支气管扩张剂治疗D组慢性阻塞性肺疾病的药物经济学评价

Pharmacoeconomic Analysis of Long-acting Anticholinergic Drugs/Long-acting β Receptor Agonists Bronchodilator in Treatment of Chronic Obstructive Pulmonary Disease in Group D

目的探讨茚达特罗格隆和溴铵噻托溴铵干粉联合福莫特罗两组方案治疗慢性阻塞性肺疾病(COPD)稳定期D组患者的成本-效果。方法选取2019年6—12月衡阳市第三人民医院收治的COPD稳定期D组患者50例作为研究对象,随机分为观察组与对照组,各25例。观察组吸入茚达特罗格隆溴铵吸入粉雾剂用胶囊,对照组吸入噻托溴铵干粉联合福莫特罗,比较两组BDOE指数、临床疗效、不良反应、成本-效果,并进行敏感性分析。结果观察组和对照组治疗24周末的BDOE指数分别为(4.32±2.20)分和(2.74±1.26)分,差异有统计学意义(P<0.05);观察组和对照组治疗有效率分别为92.0%和87.5%,差异无统计学意义(P>0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组和对照组成本-效果比分别为14.9和28.9,敏感度分析与成本-效果分析的结果一致。结论采用茚达特罗格隆溴铵吸入粉雾剂用胶囊治疗COPD稳定期D组患者更具成本-效果优势。

Objective To evaluate cost-effectiveness of the two schemes of indoxtillon and tiotropium dry powder combined with formoterol in the treatment of patients with chronic obstructive pulmonary disease(COPD) in group D in the stable stage. Methods A total of fifty patients with COPD in the stable stage in group D admitted to the Third People’s Hospital of Hengyang from June to December 2019 were selected as the research objects and were randomly divided into an observation group and a control group with twenty-five cases in each group. The observation group inhaled indoxtillon tiotropium inhalation powder aerosol capsules, and the control group inhaled tiotropium bromide dry powder combined with formoterol. The BDOE index, clinical efficacy, adverse reaction, and cost-effectiveness were compared and sensitivity analysis was conducted. Results The BDOE index of the observation group and the control group were(4.32±2.20) and(2.74±1.26), and the difference was statistically significant(P<0.05), the effective rate of the observation group and the control group were 92.0% and 87.5% respectively, there was no significant difference(P>0.05);there was no significant difference between the two groups in the incidence of adverse reactions(P>0.05), and the cost-effectiveness ratio of the observation group and the control group were 14.9 and 28.9, respectively, the results of the sensitivity analysis were consistent with those of the cost-effectiveness analysis. Conclusion The use of indoxtillon and tiotropium inhalation powder aerosol capsules for the treatment of patients with COPD in group D in the stable stage has a cost-effectiveness advantage.